Paroxysmal nocturnal hemoglobinuria, PNH
Clinical trials for Paroxysmal nocturnal hemoglobinuria, PNH explained in plain language.
Never miss a new study
Get alerted when new Paroxysmal nocturnal hemoglobinuria, PNH trials appear
Sign up with your email to follow new studies for Paroxysmal nocturnal hemoglobinuria, PNH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New complement inhibitor takes on established PNH drug in phase III trial
Disease control Not yet recruitingResearchers are testing an experimental drug called VSA012 against eculizumab in adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor therapy. The trial enrolls about 70 participants and compares how well each treatment controls hemolys…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Phase 3 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an oral pill tame a rare blood disease?
Disease control Not yet recruitingThis study tests whether an experimental oral drug called lanoracopan hydrochloride can safely and effectively treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break apart. The trial enrolls adults aged 18 to 75 with PNH, inclu…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug SLN12140 aims to control PNH in early trial
Disease control Not yet recruitingThis phase II trial tests the drug SLN12140 in 10 adults with PNH who have never taken complement inhibitors. The goal is to see if SLN12140 can reduce red blood cell destruction (measured by LDH levels) and improve hemoglobin. Participants receive different doses over 12 to 64 w…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH
Phase 2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC